PCRX
Pacira BioSciences·NASDAQ
--
--(--)
--
--(--)
5.73 / 10
Netural
Fund flow analysis scores 7.77/10, pointing to robust liquidity momentum; small-to-medium inflows are positive, though large-block trends are mixed. Analyst consensus is overwhelmingly bullish (Strong Buy 100%), yet historical win rates sit at only 50%, tempering conviction. Together, strong money flow and upbeat analyst sentiment partially offset but do not fully compensate for weak fundamentals and adverse technicals.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-09
InstitutionHC Wainwright & Co.
Times predicted2
Historical Win Rate50.0%
What is the market sentiment for PCRX?
- PCRX holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 5.73/10 (Netural).
